Achieve Life Sciences announces data from cytisinicline ORCA program

Achieve Life Sciences announced that three oral presentations featuring data from both of the Phase 3 ORCA-2 and ORCA-3 clinical trials of cytisinicline for smoking cessation and from the Phase 2 ORCA-V1 trial for e-cigarette cessation will be presented at the Society for Research on Nicotine and Tobacco, SRNT, Annual Meeting, being held in Edinburgh, Scotland, March 20-23, 2024. “We are appreciative of this opportunity at the SRNT Annual Meeting to share multiple data presentations that reflect the promising results we have seen in the cytisinicline ORCA program for both smoking and vaping cessation,” stated Dr. Cindy Jacobs, Achieve Chief Medical Officer. “New solutions to help the millions of people who struggle with nicotine dependence are long overdue, and we believe cytisinicline will be an important new option for those who want to quit nicotine whether they are smoking or vaping.”